Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)—The German Adjuvant Breast Cancer Group
Authors:
- Manfred KaufmannMKManfred Kaufmann
- German Adjuvant Breast Cancer GroupGGGerman Adjuvant Breast Cancer Group
- 1 November 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31) , 7842-7848
Abstract
Purpose: To investigate the effect of adjuvant sequential tamoxifen after chemotherapy in postmenopausal patients with hormone receptor–negative breast cancer. Methods: Patients were randomly assigned to oral tamoxifen (30 mg daily for 5 years; n = 421) or no additional treatment (n = 408) after risk-adapted polychemotherapy consisting of three 28-day cycles of CMF (cyclophosphamide, 500 mg/m2, methotrexate, 40 mg/m2, and fluorouracil, 600 mg/m2) in patients with negative or one to three positive lymph nodes and four 21-day cycles of epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 followed by three cycles of CMF in patients with four to nine positive lymph nodes. Results: Thirty-six percent of the patients included were older than 60 years, 63% were node negative, 13% had four to nine positive nodes, 55% had tumor grade 3, and 41% received breast-preserving surgery. At 5.3 years’ median follow-up, the first event of failure (recurrence, secondary tumor, or death) had occurred in 123 patients in the tamoxifen group and 107 patients of the control group. Event-free survival rates after 5 years were 70.3% (95% CI, 65.5% to 75.0%) and 72.8% (95% CI, 68.2% to 77.5%) for the tamoxifen and control groups, respectively. The estimated hazard ratio of tamoxifen versus control was 1.13 (95% CI, 0.87 to 1.48; P = .34), which gives no indication of an additional benefit of tamoxifen in these patients. Conclusion: This study contributes substantially to finalization of the presently emerging evidence that tamoxifen does not benefit women with receptor-negative breast cancer after chemotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Long-Term Follow-Up of Patients in Four Prospective Studies of the German Breast Cancer Study Group (GBSG): A Summary of Key ResultsOncology Research and Treatment, 2002
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trialBMJ, 1995
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI: Journal of the National Cancer Institute, 1994
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- Discrete sequential boundaries for clinical trialsBiometrika, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958